Genmab As Stock Analysis

Genmab Pink Sheet Analysis Notes

About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.2. Genmab A/S recorded earning per share (EPS) of 12.0. The entity had not issued any dividends in recent years. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.The quote for Genmab AS is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Genmab AS call Jan Winkel at 45 70 20 27 28 or check out https://www.genmab.com.

Genmab A/S Investment Alerts

Genmab Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab A/S's market, we take the total number of its shares issued and multiply it by Genmab A/S's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Genmab Profitablity

The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.

Technical Drivers

As of the 15th of February 2026, Genmab A/S retains the Downside Deviation of 3.58, risk adjusted performance of 0.0334, and Market Risk Adjusted Performance of 0.2392. Genmab A/S technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genmab A/S jensen alpha, as well as the relationship between the potential upside and skewness to decide if Genmab A/S is priced fairly, providing market reflects its last-minute price of 300.0 per share. Given that Genmab AS has jensen alpha of 0.0439, we strongly advise you to confirm Genmab A/S's regular market performance to make sure the company can sustain itself at a future point.

Genmab A/S Price Movement Analysis

Genmab A/S Predictive Daily Indicators

Genmab A/S Forecast Models

Genmab A/S's time-series forecasting models are one of many Genmab A/S's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genmab A/S's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Genmab A/S Debt to Cash Allocation

Genmab AS has accumulated 634 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Genmab A/S has a current ratio of 12.85, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genmab A/S until it has trouble settling it off, either with new capital or with free cash flow. So, Genmab A/S's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genmab A/S sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genmab to invest in growth at high rates of return. When we think about Genmab A/S's use of debt, we should always consider it together with cash and equity.

Genmab A/S Assets Financed by Debt

Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Genmab A/S's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Genmab A/S, which in turn will lower the firm's financial flexibility.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Genmab A/S prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Genmab shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Genmab A/S. By using and applying Genmab Pink Sheet analysis, traders can create a robust methodology for identifying Genmab entry and exit points for their positions.

When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.